Editas Medicine | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 7.543 M

Revenue: As of FY2025 Q3, the actual value is USD 7.543 M, beating the estimate of USD 4.945 M.

EPS: As of FY2025 Q3, the actual value is USD -0.28, beating the estimate of USD -0.3122.

EBIT: As of FY2025 Q3, the actual value is USD -23.98 M.

Cash Flow

• Cash, cash equivalents, and marketable securities as of September 30, 2025, were $165.6 million compared to $269.9 million as of December 31, 2024.
• The company raised $17.8 million of gross equity proceeds from its ATM facility for the three months ended September 30, 2025.

Net Loss

• Net loss attributable to common stockholders for the three months ended September 30, 2025, was $25.1 million, or $0.28 per share, compared to a net loss of $62.1 million, or $0.75 per share, for the same period in 2024.

Revenue

• Collaboration and other research and development revenues increased to $7.5 million for the three months ended September 30, 2025, compared to $0.1 million for the same period in 2024. The increase is primarily attributable to the recognition of revenue related to a milestone achieved under the Company’s collaboration agreement with BMS in the third quarter of 2025.

Operating Expenses

• Research and development expenses decreased by $27.9 million to $19.8 million for the three months ended September 30, 2025, compared to $47.6 million for the same period in 2024. The decrease is primarily related to reduced clinical and manufacturing costs related to the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery.
• General and administrative expenses decreased by $5.8 million to $12.3 million for the three months ended September 30, 2025, compared to $18.1 million for the same period in 2024. The decrease is primarily attributable to a reduction in employee-related expenses related to reduced headcount associated with the reduction in workforce in connection with the discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024.

Operating Loss

• Operating loss for the three months ended September 30, 2025, was $24.5 million compared to $65.7 million for the same period in 2024.

Outlook / Guidance

• The company is on track to submit an investigational new drug (IND) or clinical trial application (CTA) for EDIT-401 by mid-2026 and aims to achieve initial in vivo human proof-of-concept data for EDIT-401 by the end of 2026.
• The company has extended its cash runway into the third quarter of 2027, enabling the progression of EDIT-401 beyond initial human proof-of-concept data.